IL118519A - Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives, their preparation and pharmaceutical compositions containing them - Google Patents

Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL118519A
IL118519A IL11851996A IL11851996A IL118519A IL 118519 A IL118519 A IL 118519A IL 11851996 A IL11851996 A IL 11851996A IL 11851996 A IL11851996 A IL 11851996A IL 118519 A IL118519 A IL 118519A
Authority
IL
Israel
Prior art keywords
tetrahydroquinazolinedione
triazinedione
pyrimidinetrione
pyrimidinedione
derivatives
Prior art date
Application number
IL11851996A
Other languages
English (en)
Other versions
IL118519A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL118519A0 publication Critical patent/IL118519A0/xx
Publication of IL118519A publication Critical patent/IL118519A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL11851996A 1995-06-09 1996-05-31 Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives, their preparation and pharmaceutical compositions containing them IL118519A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48918395A 1995-06-09 1995-06-09

Publications (2)

Publication Number Publication Date
IL118519A0 IL118519A0 (en) 1996-09-12
IL118519A true IL118519A (en) 1999-12-22

Family

ID=23942748

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11851996A IL118519A (en) 1995-06-09 1996-05-31 Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives, their preparation and pharmaceutical compositions containing them

Country Status (32)

Country Link
EP (1) EP0748800B1 (no)
JP (1) JP2721147B2 (no)
KR (1) KR100446877B1 (no)
CN (1) CN1118459C (no)
AR (1) AR003428A1 (no)
AT (1) ATE201016T1 (no)
AU (1) AU710754B2 (no)
BR (1) BR9602705A (no)
CA (1) CA2178548A1 (no)
CO (1) CO4700472A1 (no)
CZ (1) CZ290004B6 (no)
DE (1) DE69612698T2 (no)
DK (1) DK0748800T3 (no)
ES (1) ES2157366T3 (no)
GR (1) GR3036307T3 (no)
HK (1) HK1013065A1 (no)
HU (1) HU223594B1 (no)
IL (1) IL118519A (no)
MA (1) MA23899A1 (no)
MY (1) MY113499A (no)
NO (1) NO309424B1 (no)
NZ (1) NZ286720A (no)
PE (1) PE46497A1 (no)
PL (1) PL188061B1 (no)
PT (1) PT748800E (no)
RU (1) RU2175322C2 (no)
SA (1) SA96170263B1 (no)
SG (1) SG45486A1 (no)
TR (1) TR970073A2 (no)
TW (1) TW340846B (no)
UY (1) UY24257A1 (no)
ZA (1) ZA964561B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271234B1 (en) 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines
ES2241169T3 (es) 1997-10-31 2005-10-16 Daiichi Suntory Pharma Co., Ltd. Derivados de arilpiperidinopropanol y arilpiperazinopropanol y productos farmaceuticos que los contienen.
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
ES2263238T3 (es) * 1998-03-30 2006-12-01 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de antagonistas alfail-adrenoceptores.
AU1979799A (en) * 1998-07-21 2000-02-14 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
BR9912318A (pt) * 1998-07-21 2001-05-02 Ranbaxy Lab Ltd Compostos de 1- (4-arilpiperazin-1-il) -w- [n- (ol, w -dicarboximido) ] alcanos de utilidade como bloqueadores uro-seletivos de 1 - adrenoceptor.
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6387909B1 (en) 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306861B1 (en) 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US6403594B1 (en) 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
US6365591B1 (en) 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
MXPA02006848A (es) 2000-01-25 2002-12-13 Neurocrine Bioscience Inc Antagonistas del receptor de la hormona liberadora de gonadotropina.
AU2231502A (en) * 2000-11-30 2002-06-11 Ranbaxy Lab Ltd 1,4-disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers
US6673796B2 (en) 2001-08-02 2004-01-06 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
DE10311065A1 (de) * 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN1867560A (zh) 2003-08-13 2006-11-22 武田药品工株式会社 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
EP1655288A1 (en) * 2004-11-05 2006-05-10 Institut Pasteur Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
JP4966017B2 (ja) 2004-12-20 2012-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−シクロプロピルメチル−４−［２−（３，３，５，５−テトラメチルシクロヘキシル）フェニル］ピペラジンの塩および結晶
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2006250388A1 (en) * 2005-05-25 2006-11-30 Eisai R & D Management Co., Ltd. Intermediate in production of [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
JP6039587B2 (ja) * 2011-03-18 2016-12-07 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子
GB201318886D0 (en) * 2013-10-25 2013-12-11 Givaudan Sa Improvements i or relating to organic compounds
HUE050986T2 (hu) 2016-03-17 2021-01-28 Hoffmann La Roche 5-etil-4-metil-pirazol-3-karboxamid származék, amely TAAR-agonista aktivitású
US20240114908A1 (en) * 2019-10-28 2024-04-11 Nippon Soda Co., Ltd. 2,6-dioxo-3,6-dihydropyrimidine compound, agricultural and horticultural bactericide, nematicide, and medical and veterinary antifungal agent
WO2022230804A1 (ja) * 2021-04-28 2022-11-03 日本曹達株式会社 農園芸用殺菌性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2727469A1 (de) * 1977-06-18 1978-12-21 Hoechst Ag Neue hexahydropyrimidine, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
JPH02184667A (ja) * 1989-01-11 1990-07-19 Meiji Seika Kaisha Ltd Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤
JPH0344379A (ja) * 1989-07-13 1991-02-26 Yamasa Shoyu Co Ltd Ｎ↑３―ピペラジノウラシル誘導体
JP2814600B2 (ja) * 1989-08-31 1998-10-22 正幸 石川 排尿障害治療剤
SG65570A1 (en) * 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament

Also Published As

Publication number Publication date
HU223594B1 (hu) 2004-09-28
AU5469096A (en) 1996-12-19
RU2175322C2 (ru) 2001-10-27
NZ286720A (en) 1998-08-26
EP0748800A2 (en) 1996-12-18
DE69612698T2 (de) 2001-12-06
TW340846B (en) 1998-09-21
IL118519A0 (en) 1996-09-12
PL314635A1 (en) 1996-12-23
EP0748800B1 (en) 2001-05-09
BR9602705A (pt) 1998-09-08
DE69612698D1 (de) 2001-06-13
PT748800E (pt) 2001-10-30
HU9601529D0 (en) 1996-07-29
AR003428A1 (es) 1998-08-05
JPH09100269A (ja) 1997-04-15
MA23899A1 (fr) 1996-12-31
AU710754B2 (en) 1999-09-30
SG45486A1 (en) 1998-01-16
CZ290004B6 (cs) 2002-05-15
TR970073A2 (tr) 1997-02-21
CN1118459C (zh) 2003-08-20
NO962412D0 (no) 1996-06-07
CN1149051A (zh) 1997-05-07
KR970001344A (ko) 1997-01-24
EP0748800A3 (en) 1996-12-27
HK1013065A1 (en) 1999-08-13
MY113499A (en) 2002-03-30
PL188061B1 (pl) 2004-12-31
ZA964561B (en) 1996-12-09
DK0748800T3 (da) 2001-08-27
SA96170263B1 (ar) 2006-05-23
KR100446877B1 (ko) 2004-11-06
CO4700472A1 (es) 1998-12-29
NO309424B1 (no) 2001-01-29
CA2178548A1 (en) 1996-12-10
CZ169696A3 (en) 1997-01-15
GR3036307T3 (en) 2001-10-31
HUP9601529A2 (hu) 1998-09-28
ES2157366T3 (es) 2001-08-16
JP2721147B2 (ja) 1998-03-04
NO962412L (no) 1996-12-10
PE46497A1 (es) 1997-12-04
HUP9601529A3 (en) 2000-02-28
ATE201016T1 (de) 2001-05-15
UY24257A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
IL118519A (en) Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives, their preparation and pharmaceutical compositions containing them
IL127056A (en) Aryl pyrimidine derivatives, their preparation and pharmaceutical compositions comprising them
HUP0400708A3 (en) Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them
IL92558A0 (en) Pharmaceutical compositions comprising pyrimidine derivatives,certain novel such derivatives and their preparation
IL117598A (en) Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them
IL116770A (en) 2,8-disubstituted quinazolinones their preparation and pharmaceutical compositions containing them
HUP0003355A3 (en) Thieno[2,3-d]pyrimidinedione derivatives and pharmaceutical compositions containing them, process for their preparation and use thereof
IL121849A0 (en) Substituted diamino-1,3,5-triazine derivatives their preparation and pharmaceutical compositions containing them
NZ304901A (en) Taxoid derivatives, preparation thereof and pharmaceutical compositions containing same
HUP0002104A3 (en) Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9601559A3 (en) Heterocyclic ring-fused pyrimidine derivatives, pharmaceutical compositions containing the same and intermediates
HUP0001125A3 (en) Fused pyrimidine derivatives and their open chain analogues, pharmaceutical compositions thereof
IL100917A0 (en) Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
HUP0104177A3 (en) Hiv replication inhibiting pyrimidines, process for their preparation and pharmaceutical compositions containing them
HUP9802323A3 (en) Pyrimidine derivatives , process for producing them and pharmaceutical compositions containing them
HUP0000851A3 (en) Novel pyrimidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IL106904A (en) Pyridylamino- ethoxybenzyl- thiazolidine-2, 4-dione derivatives, their preparation and pharmaceutical compositions containing them
HUP0000721A3 (en) Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9601176A3 (en) Amidine derivatives having adhesion-receptor antagonistic effect, pharmaceutical compositions containing the same and process for their preparation
AU7949191A (en) Novel pyrimidine derivatives which are angiotensin ii receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
SI0918059T1 (en) Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
AU7588696A (en) Pyrido{2, 3-D} pyrimidine derivatives and pharmaceutical compositions thereof
IL112589A0 (en) Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one derivatives, their preparation and pharmaceutical compositions containing them
IL120470A0 (en) Aryloxy - and arylthio-substituted pyrimidines and triazines and derivatives thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees